Premium
Generation of HLA‐DRB1*1501‐restricted p190 minor bcr–abl (e1a2)‐specific CD4 + T lymphocytes
Author(s) -
Tanaka Yuji,
Takahashi Tsuyoshi,
Nieda Mie,
Masuda Shigeo,
Kashiwase Koichi,
Ogawa Seishi,
Chiba Shigeru,
Juji Takeo,
Hirai Hisamaru
Publication year - 2000
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.2000.02018.x
Subject(s) - chromosomal translocation , human leukocyte antigen , biology , microbiology and biotechnology , philadelphia chromosome , fusion protein , antigen , immunology , virology , cancer research , chemistry , genetics , gene , recombinant dna
A small population of cells in acute lymphoblastic leukaemia is characterized by a specific translocation of the c‐ abl oncogene on chromosome 9 to the break point cluster lesion (bcr) on chromosome 22, t(9; 22)(q34; q11) (e1a2). Theoretically, the junction‐spanning sequences of oncogene fusion proteins might be ideal targets for immunotherapy because these are not present in normal cells. In this study, we show for the first time that in vitro immunization with a 17‐mer e1a2 peptide representing the p190 minor bcr–abl fusion protein resulted in HLA‐DRB1*1501‐restricted peptide‐specific proliferative CD4 + T lymphocytes, using peptide‐pulsed monocyte‐derived dendritic cells as the antigen‐presenting cells.